NewAmsterdam Pharma Financials
| NAMSW Stock | 12.51 0.24 1.96% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.5 | 8.0755 |
|
|
The essential information of the day-to-day investment outlook for NewAmsterdam Pharma includes many different criteria found on its balance sheet. An individual investor should monitor NewAmsterdam Pharma's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in NewAmsterdam Pharma.
Net Income |
|
NewAmsterdam | Select Account or Indicator |
Please note, the imprecision that can be found in NewAmsterdam Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NewAmsterdam Pharma. Check NewAmsterdam Pharma's Beneish M Score to see the likelihood of NewAmsterdam Pharma's management manipulating its earnings.
NewAmsterdam Pharma Stock Summary
NewAmsterdam Pharma competes with NewAmsterdam Pharma, Scilex Holding, and OmniAb. NewAmsterdam Pharma is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | G3710A113 N62509117 |
| Location | Netherlands |
| Business Address | Gooimeer 2-35, Naarden, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.newamsterdampharma.com |
| Phone | 31 35 206 2971 |
NewAmsterdam Pharma Key Financial Ratios
| Return On Equity | -0.46 | ||||
| Operating Margin | (3.38) % | ||||
| Revenue | 45.56 M | ||||
| Gross Profit | 45.56 M | ||||
| EBITDA | (241.49 M) |
NewAmsterdam Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NewAmsterdam Pharma's current stock value. Our valuation model uses many indicators to compare NewAmsterdam Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NewAmsterdam Pharma competition to find correlations between indicators driving NewAmsterdam Pharma's intrinsic value. More Info.NewAmsterdam Pharma is regarded third in return on equity category among its peers. It also is regarded third in return on asset category among its peers . At this time, NewAmsterdam Pharma's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NewAmsterdam Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NewAmsterdam Pharma Systematic Risk
NewAmsterdam Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. NewAmsterdam Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on NewAmsterdam Pharma correlated with the market. If Beta is less than 0 NewAmsterdam Pharma generally moves in the opposite direction as compared to the market. If NewAmsterdam Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one NewAmsterdam Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of NewAmsterdam Pharma is generally in the same direction as the market. If Beta > 1 NewAmsterdam Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in NewAmsterdam Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NewAmsterdam Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of NewAmsterdam Pharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
NewAmsterdam Pharma March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of NewAmsterdam Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of NewAmsterdam Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of NewAmsterdam Pharma based on widely used predictive technical indicators. In general, we focus on analyzing NewAmsterdam Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build NewAmsterdam Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.12 | |||
| Information Ratio | 0.0277 | |||
| Maximum Drawdown | 29.76 | |||
| Value At Risk | (10.01) | |||
| Potential Upside | 11.0 |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.